These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

524 related items for PubMed ID: 16080070

  • 1. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections.
    Bradford PA, Weaver-Sands DT, Petersen PJ.
    Clin Infect Dis; 2005 Sep 01; 41 Suppl 5():S315-32. PubMed ID: 16080070
    [Abstract] [Full Text] [Related]

  • 2. In vitro activity of tigecycline against patient isolates collected during phase 3 clinical trials for diabetic foot infections.
    Petersen PJ, Ruzin A, Tuckman M, Jones CH.
    Diagn Microbiol Infect Dis; 2010 Apr 01; 66(4):407-18. PubMed ID: 20226331
    [Abstract] [Full Text] [Related]

  • 3. Tigecycline: first of a new class of antimicrobial agents.
    Rose WE, Rybak MJ.
    Pharmacotherapy; 2006 Aug 01; 26(8):1099-110. PubMed ID: 16863487
    [Abstract] [Full Text] [Related]

  • 4. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
    Fritsche TR, Sader HS, Stilwell MG, Dowzicky MJ, Jones RN.
    Diagn Microbiol Infect Dis; 2005 Jul 01; 52(3):187-93. PubMed ID: 16105563
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. In vitro activity of tigecycline and occurrence of tetracycline resistance determinants in isolates from patients enrolled in phase 3 clinical trials for community-acquired pneumonia.
    Bradford PA, Petersen PJ, Tuckman M, Jones CH.
    Clin Microbiol Infect; 2008 Sep 01; 14(9):882-6. PubMed ID: 18844692
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Establishing the role of tigecycline in an era of antimicrobial resistance.
    Schafer JJ, Goff DA.
    Expert Rev Anti Infect Ther; 2008 Oct 01; 6(5):557-67. PubMed ID: 18847395
    [Abstract] [Full Text] [Related]

  • 10. Tigecycline: a novel glycylcycline antibiotic.
    Zhanel GG, Karlowsky JA, Rubinstein E, Hoban DJ.
    Expert Rev Anti Infect Ther; 2006 Feb 01; 4(1):9-25. PubMed ID: 16441206
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Tigecycline: a new glycylcycline for treatment of serious infections.
    Noskin GA.
    Clin Infect Dis; 2005 Sep 01; 41 Suppl 5():S303-14. PubMed ID: 16080069
    [Abstract] [Full Text] [Related]

  • 14. Use of in vitro susceptibility and pathogen prevalence data to model the expected clinical success rates of tigecycline and other commonly used antimicrobials for empirical treatment of complicated skin and skin-structure infections.
    Sader HS, Mallick R, Kuznik A, Fritsche TR, Jones RN.
    Int J Antimicrob Agents; 2007 Dec 01; 30(6):514-20. PubMed ID: 17959359
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
    Vasilev K, Reshedko G, Orasan R, Sanchez M, Teras J, Babinchak T, Dukart G, Cooper A, Dartois N, Gandjini H, Orrico R, Ellis-Grosse E, 309 Study Group.
    J Antimicrob Chemother; 2008 Sep 01; 62 Suppl 1():i29-40. PubMed ID: 18684704
    [Abstract] [Full Text] [Related]

  • 18. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004).
    Hoban DJ, Bouchillon SK, Johnson BM, Johnson JL, Dowzicky MJ, Tigecycline Evaluation and Surveillance Trial (TEST Program) Group.
    Diagn Microbiol Infect Dis; 2005 Jul 01; 52(3):215-27. PubMed ID: 16105567
    [Abstract] [Full Text] [Related]

  • 19. Tigecycline: a review of a new glycylcycline antibiotic.
    Scheinfeld N.
    J Dermatolog Treat; 2005 Jul 01; 16(4):207-12. PubMed ID: 16249141
    [Abstract] [Full Text] [Related]

  • 20. Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents.
    Sader HS, Jones RN, Stilwell MG, Dowzicky MJ, Fritsche TR.
    Diagn Microbiol Infect Dis; 2005 Jul 01; 52(3):181-6. PubMed ID: 16105562
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.